
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) – Research analysts at HC Wainwright lowered their FY2026 earnings estimates for shares of Structure Therapeutics in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst A. Ghosh now expects that the company will earn ($2.18) per share for the year, down from their previous forecast of ($1.84). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Structure Therapeutics’ Q4 2026 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.63) EPS, FY2027 earnings at ($2.40) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($2.79) EPS and FY2030 earnings at ($2.54) EPS.
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15).
Several other equities analysts have also weighed in on the company. Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Citizens Jmp reiterated a “market outperform” rating and set a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on Structure Therapeutics in a research note on Friday, August 7th. Weiss Ratings raised Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Finally, Wall Street Zen lowered Structure Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $110.91.
Check Out Our Latest Stock Report on GPCR
Structure Therapeutics Price Performance
Structure Therapeutics stock opened at $18.57 on Monday. Structure Therapeutics has a one year low of $18.38 and a one year high of $94.90. The company’s fifty day moving average price is $27.31 and its two-hundred day moving average price is $45.70.
Institutional Trading of Structure Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. IFP Advisors Inc bought a new stake in shares of Structure Therapeutics during the 2nd quarter worth $46,000. Sterling Capital Management LLC grew its stake in Structure Therapeutics by 63.6% in the 3rd quarter. Sterling Capital Management LLC now owns 3,345 shares of the company’s stock valued at $105,000 after buying an additional 1,300 shares during the last quarter. Assetmark Inc. grew its stake in Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after buying an additional 449 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Structure Therapeutics in the 3rd quarter valued at $132,000. Finally, Parallel Advisors LLC raised its holdings in Structure Therapeutics by 12.7% in the 3rd quarter. Parallel Advisors LLC now owns 8,286 shares of the company’s stock worth $259,000 after acquiring an additional 934 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.
Key Structure Therapeutics News
Investors following GPCR have been watching these news items:
- Neutral Sentiment: HC Wainwright kept its Buy rating on GPCR, offering a counterpoint to its weaker earnings outlook. HC Wainwright Has Negative Opinion of GPCR FY2026 Earnings
- Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $2.18 from a loss of $1.84, and its Q4 2026 estimate to a loss of $0.68 from $0.50. The deeper projected losses may weigh on sentiment, especially as GPCR’s current-year results have also missed consensus expectations. HC Wainwright earnings estimates
- Negative Sentiment: The firm’s forecasts point to continued losses in 2027–2030, including projected losses of $2.40 per share in 2027 and $2.70 in 2028. This outlook underscores the company’s ongoing earnings risk. Analysts Offer Predictions for GPCR Q1 Earnings
About Structure Therapeutics
Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.
Read More
- Five stocks we like better than Structure Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
